Teva, Sanofi and Crohn's disease
TEVAN.UL] failed to convince a U.S. appeals court on Friday to reverse a decision that would remove patents related to its ...
Teva Pharmaceuticals is one of the best performing stocks in the SPDR S&P Pharmaceuticals ETF ( XPH) for 2024 as the stock ...
Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, ...
17h
Orion Portfolio Solutions LLC bought a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) ...
Five patents related to Teva Pharmaceutical Industries Ltd.’s ProAir HFA asthma inhaler don’t cover the treatment’s active ingredient and must be delisted from the US Food and Drug Administration’s ...
In an order posted by the U.S. Court of Appeals for the Federal Circuit, the court affirmed a win for Amneal Pharmaceuticals (AMRX) in a ...
Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting ...
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.01% of ...
As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and ...
The companies said Tuesday that patients with ulcerative colitis who were treated with duvakitug achieved a higher rate of clinical remission compared with a placebo group. A group of patients with ...
UBS analyst Ashwani Verma raised the firm’s price target on Teva (TEVA) to $28 from $26 and keeps a Buy rating on the shares.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback